Erbitux Plus Chemo Improves Lung Cancer Outcomes
May 31st, 2008
The long-awaited results of a trial of the biologic drug Erbitux on patients with advanced non-small cell lung cancer show it prolonged survival by about five weeks when combined with chemotherapy.